Toujeo

Toujeo. It is a long-acting insulin analog used in the management of type 1 diabetes and type 2 diabetes. Developed by the pharmaceutical company Sanofi, it is designed to provide a steady, prolonged release of insulin glargine to help control blood glucose levels. The medication is administered once daily via subcutaneous injection and is a concentrated formulation containing 300 units per milliliter.

Medical uses

Toujeo is indicated to improve glycemic control in adults with diabetes mellitus. It is primarily used as a basal insulin to provide a consistent background level of insulin throughout the day and night. Clinical studies, such as those published in the journal Diabetes Care, have demonstrated its efficacy in reducing HbA1c levels in patients with type 2 diabetes. It may be used in combination with other anti-diabetic agents, including rapid-acting insulin at mealtimes or oral hypoglycemic agents. The U.S. Food and Drug Administration and the European Medicines Agency have approved its use based on evidence from the EDITION clinical trial program.

Side effects

The most common adverse reaction associated with Toujeo is hypoglycemia, which can be severe and may require assistance from another person. Other frequently reported side effects include injection site reactions, such as pain, redness, or swelling. Weight gain and peripheral edema have also been observed in some patients. As with all insulin therapies, there is a risk of allergic reactions, including anaphylaxis. The prescribing information includes warnings about potential hypokalemia and advises monitoring of blood glucose levels to mitigate risks.

Pharmacology

Toujeo contains insulin glargine, which is a recombinant DNA human insulin analog. Its mechanism of action involves binding to the insulin receptor on cells, such as those in skeletal muscle and adipose tissue, to facilitate the uptake of glucose. The formulation is designed to form a subcutaneous depot upon injection, resulting in a slow, steady release into the bloodstream. Pharmacokinetic studies show it has a flatter and more prolonged profile compared to its predecessor, Lantus. Its metabolism occurs primarily in the liver and kidneys, following the pathways of endogenous insulin.

History

Insulin glargine was first approved for medical use in the United States in 2000 under the brand name Lantus. Sanofi developed Toujeo as a higher-concentration formulation, which received approval from the European Commission in 2014 and from the FDA in 2015. The development was driven by the goal of creating a basal insulin with an even more stable pharmacokinetic profile. Key clinical trials, including the EDITION 1 and EDITION 2 studies, were conducted to establish its safety and efficacy versus insulin glargine 100 units/mL.

Society and culture

Toujeo is a significant product within the global insulin market, competing with other long-acting analogs like Levemir from Novo Nordisk and Tresiba. Its introduction sparked discussions about the cost of diabetes medications and access to healthcare. The drug has been the subject of direct-to-consumer advertising in the United States and is included in the formularies of many health insurance plans. Organizations like the American Diabetes Association provide guidelines on its use within comprehensive diabetes management strategies.